rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19

INTRODUCTION: Numerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In contrast, drugs based on monoclonal antibodies, enab...

Descripción completa

Detalles Bibliográficos
Autores principales: Esmagambetov, Ilias B., Ryabova, Ekaterina I., Derkaev, Artem A., Shcheblyakov, Dmitry V., Dolzhikova, Inna V., Favorskaya, Irina A., Grousova, Daria M., Dovgiy, Mikhail A., Prokofiev, Vladimir V., Gosudarev, Andrey I., Byrikhina, Daria V., Zorkov, Ilia D., Iliukhina, Anna A., Kovyrshina, Anna V., Shelkov, Artem Y., Naroditsky, Boris S., Logunov, Denis Y., Gintsburg, Alexander L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098153/
https://www.ncbi.nlm.nih.gov/pubmed/37063833
http://dx.doi.org/10.3389/fimmu.2023.1129245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098153/
https://www.ncbi.nlm.nih.gov/pubmed/37063833
http://dx.doi.org/10.3389/fimmu.2023.1129245

Ejemplares similares